Inclusion Criteria:

          -  Participants must have Eastern Cooperative Oncology Group (ECOG) performance status
             grade of 0 or 1

          -  Participants must have cardiac parameters within the following range: corrected QT
             interval (QTcF) less than or equal to <= 480 milliseconds based on the average of
             triplicate assessments performed as close as possible in succession (the full set of
             triplicates should be completed in less than 10 minutes)

          -  Women of childbearing potential must have a negative highly sensitive serum pregnancy
             test (example: beta human chorionic gonadotropin [beta-hCG]) at screening, and a
             negative serum or urine pregnancy test prior to the first dose of study drug

          -  Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for a period of at least 30 days after the last
             study drug administration

          -  Participants must be willing and able to adhere to the lifestyle restrictions
             specified in this protocol

        Exclusion Criteria:

          -  Participant has known active central nervous system (CNS) involvement

          -  Participant has received prior solid organ transplantation

          -  Participant has known allergies, hypersensitivity, or intolerance to JNJ-64264681 or
             its excipients

          -  Participant has been treated with an investigational drug (including investigational
             vaccines) within five half-lives or 2 weeks before the planned first dose of study
             drug

          -  Participant is experiencing toxicities from previous anticancer therapies that have
             not resolved to baseline levels, or to Grade 1 or less (except for alopecia and
             peripheral neuropathy)